StockData
HCW Biologics Inc. logo

HCW Biologics Inc. (HCWB) stock

HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3095% below fair value
$0.76−0.01 (-1.65%)

Close on Nov 18, 2026Market cap $1.40MP/E –Yield –

HCW Biologics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

HCW Biologics's ebitda for the twelve months ending Jun 30, 2026 was -$7.08M. For fiscal 2025 it was -$12.12M. The highest annual figure on record is -$5.25M in fiscal 2020.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.12M–
FY2024Dec 31, 2024-$28.27M–
FY2023Dec 31, 2023-$24.58M–
FY2022Dec 31, 2022-$14.36M–
FY2021Dec 31, 2021-$12.82M–
FY2020Dec 31, 2020-$5.25M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.04M–
Q1 FY2026Mar 31, 2026$3.38M–
Q4 FY2025Dec 31, 2025-$4.30M–
Q3 FY2025Sep 30, 2025-$3.12M–
Q2 FY2025Jun 30, 2025-$3.17M–
Q1 FY2025Mar 31, 2025-$1.55M–
Q4 FY2024Dec 31, 2024-$2.46M–
Q3 FY2024Sep 30, 2024-$3.56M–
Q2 FY2024Jun 30, 2024-$15.01M–
Q1 FY2024Mar 31, 2024-$7.25M–
Q4 FY2023Dec 31, 2023-$10.49M–
Q3 FY2023Sep 30, 2023-$4.80M–
Q2 FY2023Jun 30, 2023-$4.23M–
Q1 FY2023Mar 31, 2023-$5.06M–
Q4 FY2022Dec 31, 2022-$5.41M–
Q3 FY2022Sep 30, 2022-$3.86M–
Q2 FY2022Jun 30, 2022-$3.36M–
Q1 FY2022Mar 31, 2022-$1.74M–
Q4 FY2021Dec 31, 2021-$3.01M-236.5%
Q3 FY2021Sep 30, 2021-$3.97M–
Q2 FY2021Jun 30, 2021-$2.60M–
Q1 FY2021Mar 31, 2021-$3.25M–
Q4 FY2020Dec 31, 2020$2.20M–
Q3 FY2020Sep 30, 2020-$2.58M–

More HCW Biologics figures

See a number that looks wrong?